Table 1.
Clinical Features | Total (n) | PGC-1α Expression | χ2 | P | ERRα Expression | χ2 | P | PGC-1α/ERRα Expression | χ2 | P | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
High | Low | High | Low | High/High | Neither High | ||||||||
Age, years | 0.032 | 0.859 | 0.095 | 0.758 | 0.033 | 0.856 | |||||||
<55 | 42 | 17 | 8 | 15 | 10 | 11 | 14 | ||||||
≥55 | 12 | 5 | 11 | 6 | 7 | 10 | |||||||
Tumor size, cm | 3.459 | 0.063 | 0.119 | 0.73 | 1.073 | 0.3 | |||||||
<10 | 41 | 21 | 5 | 17 | 9 | 13 | 13 | ||||||
≥10 | 8 | 7 | 9 | 6 | 5 | 10 | |||||||
Tumor differentiation | 4.786 | 0.029 | 6.275a | 0.027 | 5.451a | 0.04 | |||||||
Well, moderate | 37 | 6 | 8 | 6 | 8 | 3 | 11 | ||||||
Poor | 18 | 5 | 19 | 4 | 14 | 9 | |||||||
FIGO stage | 0.149 | 0.699 | 1.036 | 0.309 | 0.717 | 0.397 | |||||||
Ⅰ–Ⅱ | 41 | 14 | 5 | 10 | 9 | 7 | 12 | ||||||
III–Ⅳ | 15 | 7 | 15 | 7 | 11 | 11 | |||||||
Lymph node status | 1.332a | 0.425 | 5.772a | 0.023 | 7.161a | 0.021 | |||||||
Absent | 32 | 13 | 8 | 10 | 11 | 5 | 16 | ||||||
Present | 9 | 2 | 10 | 1 | 8 | 3 | |||||||
CA125, U/mL | 0.497 | 0.481 | 4.388 | 0.036 | 5.802a | 0.021 | |||||||
<78 | 42 | 8 | 5 | 5 | 8 | 2 | 11 | ||||||
≥78 | 21 | 8 | 21 | 8 | 16 | 13 | |||||||
CA153, U/mL | 2.844 | 0.092 | 2.085 | 0.149 | 3.635a | 0.078 | |||||||
<14.8 | 38 | 5 | 6 | 5 | 6 | 2 | 9 | ||||||
≥14.8 | 20 | 7 | 19 | 8 | 14 | 13 | |||||||
HE4, U/mL | 0.296 | 0.67 | 5.625a | 0.025 | 4.568a | 0.05 | |||||||
<75.5 | 34 | 6 | 3 | 2 | 7 | 1 | 8 | ||||||
≥75.5 | 19 | 6 | 17 | 8 | 13 | 12 |
Notes: aFisher test was performed. The rest of the scores were from Chi-square test.
Abbreviations: ERRα, estrogen-related receptor α; PGC-1α, peroxisome proliferator-activated receptor gamma coactivator 1-alpha.